APLM (Apollomics) ROCE % : -220.04% (As of Jun. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Apollomics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Apollomics's annualized ROCE % for the quarter that ended in Jun. 2024 was -220.04%.

Apollomics ROCE % Historical Data

The historical data trend for Apollomics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apollomics ROCE % Chart

Apollomics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

ROCE %

-47.41

-70.75

-276.69

-325.52

Apollomics Semi-Annual Data
	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
ROCE %	Get a 7-Day Free Trial			-6.86	-629.42	-496.45	-88.08	-220.04

Apollomics ROCE % Calculation

Apollomics's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-172.441	/	( ( (76.475 - 12.357)	+	(55.387 - 13.556) )	/ 2 )
	=	-172.441	/	( (64.118	+	41.831)	/ 2 )
	=	-172.441	/	52.9745
	=	-325.52 %

Apollomics's ROCE % of for the quarter that ended in Jun. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	-70.144	/	( ( (55.387 - 13.556)	+	(34.573 - 12.649) )	/ 2 )
	=	-70.144	/	( ( 41.831	+	21.924 )	/ 2 )
	=	-70.144	/	31.8775
	=	-220.04 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

Apollomics (NAS:APLM) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Apollomics ROCE % Related Terms

Thank you for viewing the detailed overview of Apollomics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Apollomics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Apollomics Inc (NAS:APLM) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

APLMW:USA

Address

989 East Hillsdale Boulevard, Suite 220, Foster, CA, USA, 94404

Website

https://www.apollomicsinc.com

Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.